Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer

In total, 70 patients were enrolled into this phase II study, to evaluate the activity of the pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) combination in recurrent ovarian cancer patients. PLD, 30 mg m(−2), was administered on day 1 by 60′ i.v. infusion, followed by GEM, 1000 mg m(−2)...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: D'Agostino, G, Ferrandina, G, Ludovisi, M, Testa, A, Lorusso, D, Gbaguidi, N, Breda, E, Mancuso, S, Scambia, G
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 2003
Fag:
Clinical
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2394291/
https://ncbi.nlm.nih.gov/pubmed/14520442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601284
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker